0001515673N/AEX-FILING FEES000151567312026-06-122026-06-1200015156732026-06-122026-06-12000151567322026-06-122026-06-12xbrli:purexbrli:sharesiso4217:USD

 

Exhibit 107

 

Calculation of Filing Fee Tables

 

 

FORM S-8

(Form Type)

 

ULTRAGENYX PHARMACEUTICAL INC.

(Exact Name of Registrant as Specified in its Charter)

 

Table 1: Newly Registered Securities
 

 

Security Type

Security Class Title

Fee Calculation Rule

Amount Registered

Proposed Maximum
Offering Price Per Unit

Maximum
Aggregate
Offering Price

Fee Rate

Amount of
Registration Fee

1

Equity

Common stock, $0.001 par value per share

Rule 457(c) and

Rule 457(h)

3,000,000

$21.84

$65,520,000

0.0001381

$9,048.31

2

Equity

Common stock, $0.001 par value per share

Rule 457(c) and

Rule 457(h)

400,000

$21.84

$8,736,000

0.0001381

$1,206.44

 

Total Offering Amounts

 

$74,256,000

 

$10,254.75

 

Total Fee Offsets

 

 

 

 

Net Fee Due

 

 

 

$10,254.75

 

1.
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8 (this “Registration Statement”) shall also cover any additional shares of common stock, par value $0.001 per share (the “Common Stock”), of Ultragenyx Pharmaceutical Inc. (the “Registrant”) that become issuable under the Ultragenyx Pharmaceutical Inc. 2023 Incentive Plan (as amended and restated, the “2023 Plan”). The “Amount Registered” represents 3,000,000 shares of Common Stock authorized for issuance under the 2023 Plan. The “Proposed Maximum Offering Price Per Unit” and “Maximum Aggregate Offering Price” are estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and (h) under the Securities Act, and are based on the average of the high and low sale prices of the Common Stock, as quoted on The Nasdaq Global Select Market, on June 8, 2026.
2.
Pursuant to Rule 416(a) under the Securities Act, this Registration Statement shall also cover any additional shares of Common Stock that become issuable under the Ultragenyx Pharmaceutical Inc. Employment Inducement Plan (as amended, the “Inducement Plan”). The “Amount Registered” represents 400,000 shares of Common Stock authorized for issuance under the Inducement Plan. The “Proposed Maximum Offering Price Per Unit” and “Maximum Aggregate Offering Price” are estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and (h) under the Securities Act, and are based on the average of the high and low sale prices of the Common Stock, as quoted on The Nasdaq Global Select Market, on June 8, 2026.